Spiegazione semplice
Ordinary CAR-T therapy is made individually from each patient's own cells, which takes weeks and costs a great deal. CTX112 starts from a healthy donor instead and uses several simultaneous CRISPR edits to stop the donor cells attacking the patient and to slow the patient's immune system destroying them — so one batch can serve many people, off the shelf.
Approfondisci
CTX112 is an allogeneic anti-CD19 CAR-T candidate from CRISPR Therapeutics incorporating multiple edits to remove the endogenous T-cell receptor and MHC class I, plus potency edits intended to improve persistence. It is in trials in B-cell malignancies and has been explored in autoimmune indications; it holds FDA Regenerative Medicine Advanced Therapy designation.
Sources
- CRISPR Therapeutics
CRISPR Therapeutics pipeline ↗